mTOR and cancer therapy
- PMID: 17041628
- DOI: 10.1038/sj.onc.1209886
mTOR and cancer therapy
Abstract
Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the targets of the mTOR kinase, are overexpressed or mutated in cancer. Rapamycin, the naturally occurring inhibitor of mTOR, along with a number of recently developed rapamycin analogs (rapalogs) consisting of synthetically derived compounds containing minor chemical modifications to the parent structure, inhibit the growth of cell lines derived from multiple tumor types in vitro, and tumor models in vivo. Results from clinical trials indicate that the rapalogs may be useful for the treatment of subsets of certain types of cancer. The sporadic responses from the initial clinical trials, based on the hypothesis of general translation inhibition of cancer cells are now beginning to be understood owing to a more complete understanding of the dynamics of mTOR regulation and the function of mTOR in the tumor microenvironment. This review will summarize the preclinical and clinical data and recent discoveries of the function of mTOR in cancer and growth regulation.
Similar articles
-
An expanding role for mTOR in cancer.Trends Mol Med. 2005 Aug;11(8):353-61. doi: 10.1016/j.molmed.2005.06.007. Trends Mol Med. 2005. PMID: 16002336 Review.
-
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.Cell Mol Biol Lett. 2005;10(3):479-98. Cell Mol Biol Lett. 2005. PMID: 16217558 Review.
-
Defining the role of mTOR in cancer.Cancer Cell. 2007 Jul;12(1):9-22. doi: 10.1016/j.ccr.2007.05.008. Cancer Cell. 2007. PMID: 17613433 Review.
-
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.Brain. 2009 Jun;132(Pt 6):1509-22. doi: 10.1093/brain/awp093. Epub 2009 May 4. Brain. 2009. PMID: 19416948
-
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.J BUON. 2006 Jul-Sep;11(3):267-76. J BUON. 2006. PMID: 17309148 Review.
Cited by
-
Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4. Clin Med Insights Oncol. 2012. PMID: 22253554 Free PMC article.
-
Elevation of n-3/n-6 PUFAs ratio suppresses mTORC1 and prevents colorectal carcinogenesis associated with APC mutation.Oncotarget. 2016 Nov 22;7(47):76944-76954. doi: 10.18632/oncotarget.12759. Oncotarget. 2016. PMID: 27769066 Free PMC article.
-
MiRNA Profiles of Extracellular Vesicles Secreted by Mesenchymal Stromal Cells-Can They Predict Potential Off-Target Effects?Biomolecules. 2020 Sep 22;10(9):1353. doi: 10.3390/biom10091353. Biomolecules. 2020. PMID: 32971982 Free PMC article.
-
Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism.Chem Res Toxicol. 2010 Mar 15;23(3):608-19. doi: 10.1021/tx900351q. Chem Res Toxicol. 2010. PMID: 20148532 Free PMC article.
-
Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.Adv Enzyme Regul. 2010;50(1):285-307. doi: 10.1016/j.advenzreg.2009.10.016. Epub 2009 Nov 4. Adv Enzyme Regul. 2010. PMID: 19895837 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous